---
document_datetime: 2026-02-17 11:41:57
document_pages: 9
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/arexvy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: arexvy-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 6.2139617
conversion_datetime: 2026-02-21 12:19:45.464759
docling_version:
  docling-serve: 1.13.0
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.1
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
## AREXVY

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                              |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------|
| Variation type II /  | C.I.6 Change(s) to therapeutic indication(s) | 11/12/2025                          | 19/01/2026                                  | SmPC and PL                      | Please refer to Scientific Discussion 'Arexvy-H-C- - |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000276225                     | - C.I.6.a Addition of a new therapeutic indication or modification of an approved one - Accepted Extension of indication to include active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in adults 18 years of age and older for AREXVY, based on results from study 222253 (RSV OA=ADJ- 025); this is a Phase 3b, open-label study to evaluate the non-inferiority of the immune response and to evaluate the safety of the RSVPreF3 OA investigational vaccine in adults 18-49 years of age at increased risk of respiratory syncytial virus disease, compared to older adults ≥60 years of age. As a consequence, sections 4.1, 4.6, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Version 3.0 of the RMP has also been submitted. In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce   |            |            |             | II- EMA/VR/0000276225'                                                                                                                                                                                                                                                                                                                     |
|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000290199 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 16/10/2025 | 19/01/2026 | SmPC and PL | Following the submission of the final study results of study RSV OA=ADJ-013, section 4.5 of the SmPC of Arexvy (RSVPreF3 OA)has been updated to indicate that Arexvy can be co-administered with a COVID-19 mRNA vaccine. Non-inferiority of the co-administration compared to RSVPreF3 OA vaccine administered alone was demonstrated for |

<div style=\"page-break-after: always\"></div>

|                                       | Update of section 4.5 of the SmPC to add information on the co-administration with COVID-19 mRNA vaccine based on final report from study RSV OA=ADJ-013. This is a Phase 3, open-label, randomized, controlled study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with a COVID-19 mRNA vaccine (Omicron XBB.1.5) in adults aged 50 years and above. The Package Leaflet is updated accordingly.   |            |            |                        | RSV-A (GMT ratio: 1.12 (95% CI:0.97-1.28)) and RSV-B (GMT:1.08 (95% CI: 0.94 - 1.23)). However, non-inferiority of the co-administration compared to COVID-19 mRNA vaccine administered alone could not be demonstrated based on SARS- CoV-2 neutralising antibodies (GMT ratio: 1.31 (95% CI: 1.13 - 1.51)). The pre-specified non- inferiority margin of 1.5 was slightly exceeded. Of note, an analysis based on the exposed set population met the pre-specified criteria based on SARS-CoV-2 neutralising antibodies (GMT ratio:1.28 (95% CI: 1.11, 1.47)). In the absence of a correlate of protection, the clinical relevance of the reduced response for SARS-CoV-2 is unknown and it should not prevent co-administration of Arexvy and a COVID-19 mRNA vaccine. Co-administration of RSVPreF3 OA and a COVID-19 mRNA vaccine was not associated with a clinically relevant increased risk of ADRs compared to when the vaccines were administered separately, and the safety profile of RSVPreF3 OA and COVID-19 mRNA vaccine when co-administered is comparable to the known safety profile of these two vaccines administered alone. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000264399 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. C.I HUMAN AND VETERINARY MEDICINAL                                                                                                                                                                                                                                                                                             | 18/09/2025 | 19/01/2026 | SmPC, Labelling and PL | Following the submission of the final study results of study RSV OA=ADJ-020, the section 4.5 of the SmPC of Arexvy and Shingrix has been updated to indicate that both vaccines can be co-administered. The primary objectives were met as non-inferiority was demonstrated for the HZ/su response, as well                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.5 of the SmPC in order to add information on concomitant use with other vaccines based on final results from study RSV OA=ADJ-020. This is a Phase III, open-label, randomised, controlled, multi- country study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA investigational vaccine when co-administered with Herpes Zoster recombinant subunit (HZ/su) vaccine in adults aged 50 years and older. The Package Leaflet is updated accordingly. In addition, took the opportunity to implement   | the MAH editorial changes   |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------|

<div style=\"page-break-after: always\"></div>

|                                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |            |            |             | immunogenicity findings is unknown. Co administration of Arexvy and Shingrix was not associated with a clinically relevant increased risk of ADRs compared to when the vaccines were administered separately, and the safety profile of Arexvy and Shingrix co administered is comparable to the known safety profile of these two vaccines administered alone. The statements in 4.5 for co- administration of Arexvy and Shingrix with other vaccines were revised to ensure that only relevant information for prescribers is retained in the SmPC. For more information, please refer to the Summary of Product Characteristics.                                                                                                                                                                                                                                               |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type II / EMA/VR/0000284817 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.5 of the SmPC in order to include the possibility of co-administration of Arexvy with a pneumococcal conjugate vaccine based on results from study RSV OA=ADJ-019. This is a Phase III, open-label, randomized, controlled, multi-country study to evaluate the immune response, safety and reactogenicity of RSVPreF3 OA vaccine when co-administered with 20-valent pneumococcal conjugate vaccine (PCV20) in adults aged 60 years and older. The Package | 18/09/2025 | 19/01/2026 | SmPC and PL | SmPC new text Following the submission of the final study results of study RSV OA=ADJ-019, section 4.5 of the SmPC of Arexvy (RSVPreF3 OA)has been updated to indicate that Arexvy can be co- administered with 20-valent pneumococcal conjugate vaccine (PCV20). The primary objectives were met as non-inferiority was demonstrated for RSV-A and RSV-B as well as for the response to all 20 PCV20 serotypes. For RSV-A and RSV-B, adjusted GMT ratios were 1.06 and 1.00, respectively suggesting no interference in the response to RSV-A and RSV-B due to concomitant administration with PCV20. While response to PCV20 was consistently somewhat decreased in the co-administration group, there was still a robust immune response. The clinical relevance of the reduction is not entirely clear, but similar decreases were seen for the co-administration of PCV20 and |

<div style=\"page-break-after: always\"></div>

|                                       | Leaflet is updated accordingly.                                                                                                                                                                                                                                                                                                          |            |            |             | quadrivalent influenza vaccine and were still in the same range as those observed in the registration study of PCV20. Co-administration of RSVPreF3 OA and PCV20 was not associated with a clinically relevant increased risk of ADRs compared to when the vaccines were administered separately, and the safety profile of RSVPreF3 OA and PCV20 when co- administered is comparable to the known safety profile of these two vaccines administered alone. For more information, please refer to the Summary of Product Characteristics.   |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA / EMA/VR/0000280705 | B.III.2 Change to comply with Ph. Eur. or with a national pharmacopoeia of a Member State - B.III.2.z To reflect compliance with the Ph.Eur. and remove reference to the internal test method and test method number for active substances, excipients, active substance starting materials and immediate packaging materials - Accepted | 31/07/2025 |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Variation type IB / EMA/VR/0000278249 | B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.e Other changes to a test procedure (including replacement or addition) for the active substance or a starting material/intermediate - Accepted                      | 15/07/2025 |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| PSUR / EMA/PSUR/0000248473            |                                                                                                                                                                                                                                                                                                                                          | 19/06/2025 | 18/08/2025 | SmPC and PL | Variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |

<div style=\"page-break-after: always\"></div>

|                     | In view of available data on Guillain-Barré syndrome from clinical trial(s), the literature, spontaneous reports including in some cases a compatible temporal relationship and the information from the SCCS performed by FDA, the PRAC considers that a causal relationship between respiratory syncytial virus, glycoprotein f, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E and Guillain-Barré syndrome is at least a reasonable possibility. The PRAC concluded that the product information of products containing respiratory syncytial virus, glycoprotein f, recombinant, stabilised in the pre-fusion conformation, adjuvanted with AS01E should be amended accordingly.   |            |                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------------|
| Variation type II / | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.13 Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority - Accepted Submission of the final report from study 219238 (RSV OA=ADJ-018). This is a phase 3, observer-blind, randomized, placebo- controlled study to evaluate the non- inferiority of the immune response and safety of the RSVPreF3 OA investigational vaccine in adults 50-59 years of age, including adults at increased risk of respiratory syncytial virus lower respiratory                                                                                                                                      | 08/05/2025 | EMA/VR/0000255022 |

<div style=\"page-break-after: always\"></div>

|                                       | tract disease, compared to older adults ≥60 years of age.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |            |            |      |                   |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-------------------|
| Variation type II /                   | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 5.1 of the SmPC in order to update efficacy information based on final results from study 212494 (RSV OA=ADJ- 006). This is a phase 3, randomized, placebo-controlled, observer blind, multi- country study to demonstrate the efficacy of a single dose and annual revaccination of GSK's RSVPreF3 OA investigational vaccine in adults aged 60 years and above. In addition, the MAH took the opportunity to | 25/04/2025 | 18/08/2025 | SmPC | EMA/VR/0000236493 |
| Variation type II / EMA/VR/0000232276 | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. B.II.c.2 Change in test procedure for an excipient - B.II.c.2.c Substantial change to or replacement of a biological/ immunological/ immunochemical test method or a method using a biological                                                                                                                                                                                                                                                                                                          | 13/02/2025 |            |      |                   |

<div style=\"page-break-after: always\"></div>

|                     | reagent - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |            |                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------------|
| Variation type IB / | B.I.b) Control of active substance - B.I.b.z Other variation - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                                                  | 10/01/2025 | EMA/VR/0000240861 |
| Variation type IB / | This was an application for a group of variations. B.I.b.2 Change in test procedure for active substance or starting material/reagent/intermediate used in the manufacturing process of the active substance - B.I.b.2.z Other changes - Accepted B.II.b.3 Change in the manufacturing process of the finished product, including an intermediate used in the manufacture of the finished product - B.II.b.3.z Other changes - Accepted B.II.d.2 Change in test procedure for the finished product - B.II.d.2.z Other changes - Accepted | 03/12/2024 | EMA/VR/0000236022 |